Femasys inc. announces enrollment completion for stage 2 study of fembloc for permanent birth control

Company remains on track to file an investigational device exemption (ide) for a pivotal trial to support a pre-market authorization (pma) in the first quarter of 2023 company remains on track to file an investigational device exemption (ide) for a pivotal trial to support a pre-market authorization (pma) in the first quarter of 2023
FEMY Ratings Summary
FEMY Quant Ranking